The results of SMR analysis implied that genetically proxied HMGCR inhibition was associated with a lower risk of RA in whole blood (OR = 0.48, 95%CI: 0.29, 0.82, P = 6.86 × 10− 03, HEIDI = 0.125) and skeletal muscle site (OR = 0.75, 95%CI: 0.56, 0.99, P = 4.48 × 10− 02, HEIDI = 0.187) (Table S25). The gene discussed is HMGCR; the disease is rheumatoid arthritis.